Haemophilus adherence and penetration proteins

Details Haemophilus adherence and penetration proteins Haemophilus adherence and penetration proteins

1994-08-25

2001-06-12

Graser, Jennifer (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S190100, C530S350000, C435S069100, C435S069300

Reexamination Certificate

active

06245337

ABSTRACT:

FIELD OF THE INVENTION
The invention relates to Haemophilus adhesion and penetration proteins, nucleic acids, and vaccines.
BACKGROUND OF THE INVENTION
Most bacterial diseases begin with colonization of a particular mucosal surface (Beachey et al., 1981, J. Infect. Dis. 143:325-345). Successful colonization requires that an organism overcome mechanical cleansing of the mucosal surface and evade the local immune response. The process of colonization is dependent upon specialized microbial factors that promote binding to host cells (Hultgren et al., 1993 Cell, 73:887-901). In some cases the colonizing organism will subsequently enter (invade) these cells and survive intracellularly (Falkow, 1991, Cell 65:1099-1102).
Haemophilus influenzae
is a common commensal organism of the human respiratory tract (Kuklinska and Kilian, 1984, Eur. J. Clin. Microbiol. 3:249-252). It is a human-specific organism that normally resides in the human nasopharynx and must colonize this site in order to avoid extinction. This microbe has a number of surface structures capable of promoting attachment to host cells (Guerina et al., 1982, J. Infect. Dis. 146:564; Pichichero et al., 1982, Lancet ii:960-962; St. Geme et al., 1993, Proc. Natl. Acad. Sci. U.S.A. 90:2875-2879). In addition,
H. influenzae
has acquired the capacity to enter and survive within these cells (Forsgren et al., 1994, Infect. Immun. 62:673-679; St. Geme and Falkow, 1990, Infect. Immun. 58:4036-4044; St. Geme and Falkow, 1991, Infect. Immun. 59:1325-1333, Infect. Immun. 59:3366-3371). As a result, this bacterium is an important cause of both localized respiratory tract and systemic disease (Turk, 1984, J. Med. Microbiol. 18:1-16). Nonencapsulated, non-typable strains account for the majority of local disease (Turk, 1984, supra); in contrast, serotype b strains, which express a capsule composed of a polymer of ribose and ribitol-5-phosphate (PRP), are responsible for over 95% of cases of
H. influenzae
systemic disease (Turk, 1982, Clinical importance of
Haemophilus influenzae,
p. 3-9. In S.H. Sell and P. F. Wright (ed.),
Haemophilus influenzae
epidemiology, immunology, and prevention of disease. Elsevier/North-Holland Publishing Co., New York).
The initial step in the pathogenesis of disease due to
H. influenzae
involves colonization of the upper respiratory mucosa (Murphy et al., 1987, J. Infect. Dis. 5:723-731). Colonization with a particular strain may persist for weeks to months, and most individuals remain asymptomatic throughout this period (Spinola et al., 1986, I. Infect. Dis. 154:100-109). However, in certain circumstances colonization will be followed by contiguous spread within the respiratory tract, resulting in local disease in the middle ear, the sinuses, the conjunctiva, or the lungs. Alternatively, on occasion bacteria will penetrate the nasopharyngeal epithelial barrier and enter the bloodstream.
In vitro observations and animal studies suggest that bacterial surface appendages called pili (or fimbriae) play an important role in
H. influenzae
colonization. In 1982 two groups reported a correlation between piliation and increased attachment to human oropharyngeal epithelial cells and erythrocytes (Guerina et al., supra; Pichichero et al., supra). Other investigators have demonstrated that anti-pilus antibodies block in vitro attachment by piliated
H. influenzae
(Forney et al., 1992, J. Infect. Dis. 165:464-470; van Alphen et al., 1988, Infect. Immun. 56:1800-1806). Recently Weber et al. insertionally inactivated the pilus structural gene in an
H. influenzae
type b strain and thereby eliminated expression of pili; the resulting mutant exhibited a reduced capacity for colonization of year-old monkeys (Weber et al., 1991, Infect. Immun. 59:4724-4728).
A number of reports suggest that nonpilus factors also facilitate Haemophilus colonization. Using the human nasopharyngeal organ culture model, Farley et al. (1986, J. Infect. Dis. 161:274-280) and Loeb et al. (1988, Infect. Immun. 49:484-489) noted that nonpiliated type b strains were capable of mucosal attachment. Read and coworkers made similar observations upon examining nontypable strains in a model that employs nasal turbinate tissue in organ culture (1991, J. Infect. Dis. 163:549-558). In the monkey colonization study by Weber et al. (1991, supra), nonpiliated organisms retained a capacity for colonization, though at reduced densities; moreover, among monkeys originally infected with the piliated strain, virtually all organisms recovered from the nasopharynx were nonpiliated. All of these observations are consistent with the finding that nasopharyngeal isolates from children colonized with
H. influenzae
are frequently nonpiliated (Mason et al., 1985, Infect. Immun. 49:98-103; Brinton et al., 1989, Pediatr. Infect. Dis. J. 8:554-561).
Previous studies have shown that
H. influenzae
are capable of entering (invading) cultured human epithelial cells via a pili-independent mechanism (St. Geme and Falkow, 1990, supra; St. Geme and Falkow, 1991, supra). Although
H. influenzae
is not generally considered an intracellular parasite, a recent report suggests that these in vitro findings may have an in vivo correlate (Forsgren et al., 1994, supra). Forsgren and coworkers examined adenoids from 10 children who had their adenoids removed because of longstanding secretory otitis media or adenoidal hypertrophy. In all 10 cases there were viable intracellular
H. influenzae.
Electron microscopy demonstrated that these organisms were concentrated in the reticular crypt epithelium and in macrophage-like cells in the subepithelial layer of tissue. One possibility is that bacterial entry into host cells provides a mechanism for evasion of the local immune response, thereby allowing persistence in the respiratory tract.
Thus, a vaccine for the therapeutic and prophylactic treatment of Haemophilus infection is desirable. Accordingly, it is an object of the present invention to provide for recombinant Haemophilus Adherence and Penetration (HAP) proteins and variants thereof, and to produce useful quantities of these HAP proteins using recombinant DNA techniques.
It is a further object of the invention to provide recombinant nucleic acids encoding HAP proteins, and expression vectors and host cells containing the nucleic acid encoding the HAP protein.
An additional object of the invention is to provide monoclonal antibodies for the diagnosis of Haemophilus infection.
A further object of the invention is to provide methods for producing the HAP proteins, and a vaccine comprising the HAP proteins of the present invention. Methods for the therapeutic and prophylactic treatment of Haemophilus infection are also provided.
SUMMARY OF THE INVENTION
In accordance with the foregoing objects, the present invention provides recombinant HAP proteins, and isolated or recombinant nucleic acids which encode the HAP proteins of the present invention. Also provided are expression vectors which comprise DNA encoding a HAP protein operably linked to transcriptional and translational regulatory DNA, and host cells which contain the expression vectors.
The invention provides also provides methods for producing HAP proteins which comprises culturing a host cell transformed with an expression vector and causing expression of the nucleic acid encoding the HAP protein to produce a recombinant HAP protein.
The invention also includes vaccines for
Haemophilus influenzae
infection comprising an HAP protein for prophylactic or therapeutic use in generating an immune response in a patient. Methods of treating or preventing Haemophilus influenzae infection comprise administering a vaccine.


REFERENCES:
patent: 9011367 (1990-10-01), None
van Hom et al, The EMBO Journal 8: 3535-3540, 1989.*
Thomas et al, Infection & Immunity 58: 1909-1913, 1990.*
Guleg et al Infection & Immunity 44: 41-48, 1984.*
St. Geme et al Molecular Microbiology 14:217-233 1994.*
Houghten et al Vaccine 86, pp. 21-25, 1986.*
Lewin Science vol. 237, p. 1570 When Does Homology Mean Something Else? 1987.*
Reech et al, Cell vo

Affiliated with

Also associated with

Rating

Haemophilus adherence and penetration proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Haemophilus adherence and penetration proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Haemophilus adherence and penetration proteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2485147